21st ESPD Annual Meeting, 20-22 May 2022

ABSTRACT

The results of polymerase chain reaction tests for SARS-CoV-2 were positive for 4 (%9,3) patients, and the results of SARS-CoV-2 immunoglobulin G tests were positive for 39 (%90,7) patients. 21 (%48,8) of the patients had urticarial, 12 (%27,9) of them maculopapular, 5 (%11,6) patients livedoid and 1 (%2,3) patient had a skin rash compatible with pseudopernio. For patients not achieving the primary endpoints at Week 16, 33.3% and 57.8% of 135 patients initially treated with tralokinumab and transferred to open-label treatment at Week 16 achieved IGA 0/1 or EASI-75 at Week 52. With regard to skin-related QoL measured with Children's Dermatology Life Quality Index (CDLQI), 5 patients suffered from moderate QoL impairment whereas 42 individuals revealed only mild and 39 patients no QoL reduction. [Extracted from the article] Copyright of Pediatric Dermatology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)